Previous meta-analyses have evaluated genetic polymorphisms in the XRCC1 gene and likelihood for different cancers including thyroid cancer [32], breast cancer [33], glioma [34], and leukemia [35], but to our knowledge, we have performed the first meta-analysis to examine the role of the XRCC1 gene in CAD susceptibility. This evidence concerns the gene XRCC1 and leukemia.